SME Central
Home / Moved to Main Board / Indo US Bio-Tech

Indo US Bio-Tech: IPO, Share Price and Results Since Listing

Indo US Bio-Tech moved from BSE SME to the BSE main board. For Q2 FY2027 it reported revenue of INR 15.05 crore (-51.22% on a year earlier) and a loss of INR 3.67 crore.

Key Facts

Moved to
BSE main board (BSE does not publish the date)
Listed on BSE SME
11 May 2018
Symbol
INDOUS (BSE code 541304)
Latest close
INR 66.10 on 13 November 2026

Results Filed With BSE

Standalone figures, INR crore. Change compares with the same period a year earlier.

PeriodRevenueChangeProfit after taxEPS (INR)Filed
Q2 FY202715.05-51.22%-3.67-1.83after listing30 October 2026
Q1 FY202732.99+7.21%3.041.51after listing12 August 2026
Q4 FY202626.02-22.05%1.970.98after listing29 May 2026
FY2026110.44+6.36%13.126.54after listing29 May 2026
Q3 FY202622.80–31.49after listing21 January 2026
Q2 FY202630.85–3.451.72after listing29 November 2025
Q1 FY202630.77–4.702.35after listing13 August 2025
Q4 FY202533.38–3.681.86after listing27 May 2025
FY2025103.84–16.278.12after listing27 May 2025

Promoter Holding

Promoter holding has moved from 70.17% on 31 December 2025 to 68.29% on 30 September 2026 (-1.88 percentage points).

As ofPromotersPublic
30 September 202668.29%31.71%
30 June 202668.29%31.71%
31 March 202668.29%31.71%
31 December 202570.17%29.83%

Sources: BSE filings (results XBRL, shareholding pattern, board meetings), BSE daily price files, and IPO records. Prices are not adjusted for bonus issues or splits.